Prostate Cancer Diagnostics Market By Test Type (Preliminary Tests, Confirmatory Tests); By Cancer Type (Prostate Adenocarcinoma, Rare Prostate Cancer Types); By End User (Hospitals and Hospital Laboratories, Outpatient Facilities and Diagnostic Laboratories, Specialty Cancer Centers and Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Prostate Cancer Diagnostics Market: Precision Testing Connects Early Detection With Accurate Staging – (Updated On: 21st-Sep-2026)

The Global Prostate Cancer Diagnostics Market was valued at USD 8.45 billion in 2025 and is projected to reach USD 13.72 billion by 2032, expanding at a CAGR of 7.25% during 2026–2032, according to Strategic Market Research.

 

Prostate cancer diagnostics include the tests and technologies used to identify the disease, confirm malignancy, assess tumor aggressiveness, determine its spread, and monitor recurrence. Prostate cancer represents a substantial and recurring diagnostic burden, with approximately 1.5 million new cases globally in 2024.

 

The United States is projected to record approximately 333,830 new prostate cancer cases and 36,320 deaths in 2026. Around one in eight men is expected to receive a diagnosis during their lifetime, with nearly 60% of cases occurring among men aged 65 years and older. Approximately 69% of cases are identified at the localized stage, where five-year relative survival reaches 100%. Distant-stage disease accounts for about 9% of cases and has a five-year survival rate of 40.1%.

 

Prostate biopsy represents one of the market’s largest recurring procedures. Approximately 1 million prostate biopsies are performed annually in the United States, most commonly after persistently elevated PSA results or other abnormal risk findings. Published U.S. estimates indicate that only about 25% of biopsies produce a prostate cancer diagnosis, meaning approximately 75% do not identify cancer. This gap is increasing demand for biomarkers and MRI-based assessment that can improve patient selection before biopsy.

 

Biopsy practice is also moving toward the transperineal approach to reduce infection and sepsis risk associated with transrectal sampling. In the 658-patient PREVENT trial, no infections occurred in the transperineal group, compared with four infections, or 1.4%, in the transrectal group. This transition is supporting demand for transperineal access systems, biopsy needles, ultrasound guidance, fusion-navigation platforms, and outpatient procedure equipment.

 

Advanced diagnostic technologies are improving prostate lesion detection, biopsy accuracy, staging, and recurrence assessment. Philips provides the UroNav MRI-ultrasound fusion biopsy system, which combines multiparametric MRI findings with real-time ultrasound. Lantheus Holdings provides PYLARIFY, an F-18-labelled PSMA-targeted radioactive diagnostic agent used with PET/CT imaging to locate PSMA-positive lesions in patients with suspected metastasis or recurrence indicated by rising PSA levels.

 

Overall, the large screening population, approximately one million annual U.S. biopsies, aging male demographic, and survival advantage associated with localized detection are increasing the clinical importance of accurate biomarkers, MRI-guided biopsy, transperineal sampling, molecular assessment, and PSMA-based imaging across the prostate cancer diagnostic pathway.

 

Segment Leadership—Where Diagnostic Revenue and Growth Are Concentrated

By Test Type: Confirmatory Testing Leads and Grows Fastest

Leading and Fastest-Growing Subsegment: Confirmatory Tests

Confirmatory tests lead the test-type segment with a 65% share, representing USD 5.493 billion in 2025 revenue, and are projected to expand at a CAGR of 8.08% during 2026–2032, making them the fastest-growing test category. These tests play a critical role in validating abnormal prostate screening outcomes, confirming diagnosis accuracy, and guiding appropriate treatment decisions. Repeat PSA testing helps differentiate temporary elevations from persistent risk, while advanced imaging and repeat biopsy procedures support active surveillance by identifying potentially aggressive disease that may have been missed during initial evaluation.

 

By Cancer Type: High-Volume Adenocarcinoma and High-Growth Rare Tumors

Leading Subsegment: Prostate Adenocarcinoma

Prostate adenocarcinoma dominates the market with a 96% share, generating approximately USD 8.112 billion in 2025 revenue, and is expected to expand at a CAGR of 7.15% during 2026–2032. This segment represents the primary form of prostate cancer, originating from glandular epithelial cells responsible for seminal fluid production. Its dominance is driven by its high prevalence, established diagnostic pathways, and extensive treatment demand across localized and advanced disease stages. Accurate pathological confirmation through biopsy remains essential for disease classification, staging, and selection of appropriate therapeutic strategies.

Fastest-Growing Subsegment: Rare Prostate Cancer Types

Rare prostate cancers account for a 4% share, generating USD 0.338 billion in 2025 revenue, and are projected to record the fastest CAGR of 9.65% during 2026–2032. These uncommon subtypes, including small cell neuroendocrine carcinoma, ductal carcinoma, and prostate sarcomas, differ significantly from conventional prostate adenocarcinoma due to their aggressive behavior and limited PSA expression. As standard PSA screening may fail to detect these tumors, diagnosis often requires advanced imaging, biopsy-based tissue analysis, and molecular characterization, supporting demand for specialized diagnostic and treatment approaches.

 

By End User: Hospital Scale and Outpatient Growth Reshape Diagnostic Access

Leading Subsegment: Hospitals and Hospital Laboratories

Hospitals and hospital laboratories lead with a 53% share, representing USD 4.479 billion in 2025 revenue, and are projected to expand at a CAGR of 6.60% during 2026–2032. This segment remains dominant as hospitals provide comprehensive prostate cancer diagnostic pathways, integrating clinical examinations, advanced imaging, biopsy procedures, and multidisciplinary evaluation. Hospital laboratories further strengthen this position by enabling PSA testing, histopathological analysis, Gleason grading, and biomarker assessment, which support accurate diagnosis, disease classification, and personalized treatment decisions throughout the patient care journey.

Fastest-Growing Subsegment: Outpatient Facilities and Diagnostic Laboratories

Outpatient facilities and diagnostic laboratories hold a 30% share, equivalent to USD 2.535 billion in 2025 revenue, and are projected to record the fastest CAGR of 8.70% during 2026–2032. These facilities represent the primary diagnostic pathway for prostate cancer by supporting early screening, clinical evaluation, imaging coordination, and laboratory-based confirmation. Outpatient centers enable PSA testing, digital rectal examinations, prostate biopsies, and advanced imaging workflows, while diagnostic laboratories provide critical biomarker analysis, genomic testing, and histopathological evaluation. The growing preference for minimally invasive diagnostics, decentralized testing, and faster clinical decision-making is accelerating demand across this segment.

 

By Geography: Established North American Demand and Asia-Pacific Expansion

Leading Subsegment: North America

North America holds the leading 42% share, representing USD 3.549 billion in 2025 revenue, and is projected to grow at a CAGR of 6.50% during 2026–2032. The region’s dominance is supported by advanced healthcare infrastructure, strong prostate cancer screening awareness, and increasing adoption of early diagnostic approaches. The widespread use of PSA testing and digital rectal examinations, combined with advanced imaging technologies such as MRI and PET scans, is improving cancer detection, staging accuracy, and treatment planning across the region.

Fastest-Growing Subsegment: Asia-Pacific

Asia-Pacific accounts for a 23% share, equivalent to USD 1.944 billion in 2025 revenue, and is projected to register the fastest regional CAGR of 9.60% during 2026–2032. The market is expanding rapidly due to the rising burden of prostate cancer among aging male populations, increasing awareness of early detection, and improvements in healthcare accessibility across developing economies. Countries such as China, Japan, India, and South Korea are witnessing greater adoption of PSA testing, multiparametric MRI, ultrasound-guided diagnostics, and advanced biomarker-based approaches. Growing investments in tertiary care infrastructure and precision diagnostics are further supporting the shift toward earlier and more accurate disease detection across the region.

 

Market Restraints—Diagnostic Uncertainty, Unequal Access, and Infrastructure Costs

PSA Limitations Increase False Positives and Overdiagnosis

PSA remains the most accessible preliminary test, but it is not specific to cancer. Benign prostatic hyperplasia, inflammation, infection, recent procedures, and other non-malignant conditions can increase PSA levels. The National Cancer Institute notes that no single standard routine screening test has been established for prostate cancer, reflecting continuing uncertainty over how to balance early detection against unnecessary investigation. False-positive results can generate avoidable biomarker testing, MRI examinations, biopsies, patient anxiety, and treatment of tumors that may never become clinically significant.

Unequal Access Slows MRI-First Diagnosis

Multiparametric MRI and fusion-guided biopsy require specialized scanners, prostate-imaging protocols, trained radiologists, navigation software, and coordinated urology services. These resources remain concentrated in major hospitals and cancer centers. An analysis of more than 505,000 U.S. prostate biopsies found that pre-biopsy MRI use reached 64% among first-time biopsy patients in the first half of 2026, leaving approximately one-third without MRI before tissue sampling. Access differences, imaging quality, appointment delays, and inconsistent insurance coverage restrict adoption outside larger healthcare systems.

Biomarker Validation and Reimbursement Gaps Restrict Adoption

The Prostate Health Index, 4Kscore, IsoPSA, ExoDx, PCA3, SelectMDx, and genomic classifiers evaluate different biological markers and patient populations. Their scores are therefore not directly interchangeable, and physicians must determine which test is appropriate before an initial biopsy, after a negative biopsy, during active surveillance, or following confirmed cancer.

Limited head-to-head evidence, differences in clinical cutoffs, and inconsistent payer policies can slow routine adoption. Biomarkers may reduce unnecessary biopsy, but they frequently function as additional tests rather than complete replacements for MRI and histopathology. This creates uncertainty over whether the improvement in decision-making justifies the added cost, particularly in health systems with constrained diagnostic budgets.

Biopsy Risks Persist Despite Safer Transperineal Methods

Tissue biopsy remains necessary for confirming malignancy and determining the Gleason grade group. However, biopsy can cause bleeding, urinary retention, pain, and infection. In the 658-patient PREVENT trial, the transrectal group recorded four infections, equivalent to 1.4%, compared with no infections in the transperineal group. Although the transperineal approach improves infection control, it still requires trained personnel, specialized access equipment, local anesthesia or sedation, and pathology processing.

PSMA PET Remains Limited by Infrastructure and Tumor Biology

PSMA PET requires radiotracer production, nuclear-medicine facilities, PET/CT scanners, regulatory handling, and reliable distribution within a short operating window. These requirements restrict availability in smaller hospitals and emerging healthcare markets. Reimbursement differences can also limit routine use outside high-risk staging and suspected recurrence.

PSMA expression is not uniform across every prostate tumor. The FDA label for PYLARIFY states that tumors without sufficient PSMA expression may not be visualized, while uptake can also occur in tissues or conditions unrelated to prostate cancer. PSMA PET therefore improves staging accuracy but cannot eliminate the need for clinical correlation, pathology, MRI, or other imaging methods

 

Competitive Landscape—Integrated Platforms Compete Across the Diagnostic Pathway

F. Hoffmann-La Roche—Building an End-to-End Laboratory and Molecular Diagnostics Position

Roche holds one of the broadest positions in prostate cancer diagnostics, spanning Elecsys total and free PSA immunoassays, cobas laboratory systems, Ventana digital pathology and tissue-staining solutions, and comprehensive genomic profiling through Foundation Medicine. This integrated portfolio allows Roche to participate from preliminary blood testing through tissue characterization and treatment-linked molecular testing.

Foundation Medicine’s FoundationOne Liquid CDx has FDA authorization as a companion diagnostic for detecting BRCA1 and BRCA2 alterations in metastatic castration-resistant prostate cancer, supporting patient selection for targeted treatment. Roche’s advantage is therefore not dependent on one diagnostic procedure; it combines recurring PSA-test volumes with pathology, sequencing, and precision-oncology applications.

Philips—Connecting MRI Findings With Targeted Biopsy

Philips is a leading participant in image-guided prostate biopsy through its UroNav and DynaCAD platforms. UroNav combines previously captured multiparametric MRI with real-time ultrasound, electromagnetic tracking, and navigation to direct biopsy needles toward suspicious lesions. DynaCAD supports prostate MRI visualization, lesion review, reporting, and procedure planning, creating an integrated workflow between radiologists and urologists.

The commercial position of this technology is supported by the rapid movement toward MRI-first diagnosis. An analysis of more than 505,000 U.S. prostate biopsies found that pre-biopsy MRI use among first-time biopsy patients increased from 14% in 2017 to 64% during the first half of 2026. In the PRECISION trial, MRI-targeted biopsy detected clinically significant cancer in 38% of patients compared with 26% using standard biopsy, while allowing 28% of participants to avoid biopsy altogether. These modality-level findings support adoption of fusion-navigation systems such as UroNav.

Lantheus Holdings—Expanding PSMA PET Access Through PYLARIFY

Lantheus holds a strong position in advanced prostate cancer imaging through PYLARIFY, an F-18-labelled PSMA-targeted radioactive diagnostic agent. PYLARIFY is used with PET imaging to detect PSMA-positive lesions in men with suspected metastasis before definitive treatment and in patients with suspected recurrence following elevated PSA results.

In the CONDOR study, PYLARIFY detected at least one lesion in approximately 59%–66% of patients with biochemical recurrence and uninformative conventional imaging. Its results changed intended clinical management in approximately 64% of evaluable patients. In March 2026, the FDA approved PYLARIFY TruVu, a higher-concentration formulation expected to increase production batch capacity by approximately 50%, improving distribution to areas with limited access to PSMA PET.

Other Companies Supporting the Diagnostic Ecosystem

• Siemens Healthineers: Supplies PSA immunoassays, prostate MRI systems, PET/CT scanners, and imaging software used across screening, lesion assessment, staging, and recurrence detection.

• Abbott Laboratories: Provides laboratory immunoassay platforms and PSA-testing solutions used in hospital and independent diagnostic laboratories.

• Becton, Dickinson and Company: Supplies biopsy needles, tissue-collection devices, and disposable accessories for transrectal and transperineal prostate sampling.

• Telix Pharmaceuticals: Competes in PSMA PET imaging through gallium-68-based agents, including Illuccix and Gozellix, for metastatic and recurrent-disease localization.

• MDxHealth: Provides SelectMDx, ConfirmMDx, and the Genomic Prostate Score for pre-biopsy risk assessment, repeat-biopsy decisions, and tumor-aggressiveness evaluation.

• Myriad Genetics: Offers the Prolaris genomic test to evaluate tumor biology and support decisions between active surveillance and immediate treatment.

• OPKO Health: Markets the 4Kscore blood test, which combines four kallikrein measurements with clinical information to estimate aggressive-cancer risk before biopsy.

• Hologic: Participates through the PROGENSA PCA3 urine-based molecular assay, primarily used to support repeat-biopsy decisions after a previous negative result.

• GE HealthCare: Supplies MRI, ultrasound, PET/CT, and visualization platforms used for prostate lesion detection, biopsy guidance, staging, and recurrence assessment.

 

Analyst Commentary—Precision Pathways Will Define Future Market Leadership

The prostate cancer diagnostics market is entering a precision-led phase in which clinical value will depend on identifying aggressive disease while minimizing unnecessary biopsies and overtreatment. Future competitive advantage will come from integrating advanced biomarkers, multiparametric MRI, AI-supported image interpretation, targeted biopsy, and PSMA PET into coordinated diagnostic pathways. Companies that generate clinically actionable results, demonstrate cost-effectiveness, and integrate smoothly with hospital workflows will be better positioned to secure reimbursement and institutional adoption. Growth opportunities will also emerge from decentralized testing, transperineal biopsy platforms, radiopharmaceutical capacity expansion, and diagnostic solutions designed for active surveillance. Ultimately, market leadership will favor companies that connect screening, localization, tissue confirmation, molecular profiling, and disease monitoring through an accessible precision-diagnostics ecosystem.

 

Prostate Cancer Diagnostics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 8.45 Billion
Revenue Forecast in 2032	USD 13.72 Billion
Overall Growth Rate	CAGR of 7.25% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Test Type, By Cancer Type, By End User, By Geography
By Test Type	Confirmatory Tests, Preliminary Tests
By Cancer Type	Prostate Adenocarcinoma, Rare Prostate Cancer Types
By End User	Hospitals and Hospital Laboratories, Outpatient Facilities and Diagnostic Laboratories, Specialty Cancer Centers and Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, The Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Large screening population, approximately one million annual U.S. biopsies, aging male demographic, survival advantage associated with localized detection, and increasing clinical importance of accurate biomarkers, MRI-guided biopsy, transperineal sampling, molecular assessment, and PSMA-based imaging
Customization Option	Available upon request